---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104105"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:41:58.540939+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Erasca reports Q4 2025 net loss $29.1M; ERAS-0015 shows early partial responses

## Summary
- Net loss per share $(0.10) for Q4 2025 vs. $(0.11) in Q4 2024; full-year net loss $124.5M ($0.44/share).
- Cash, equivalents, and marketable securities $341.8M at Dec 31, 2025; pro forma $434M after Jan 2026 $259M upsized financing.
- ERAS-0015 showed confirmed partial responses across multiple RAS-mutant tumors at 8 mg QD with favorable safety and PK.
- R&D expenses $23.2M in Q4, down from $26.1M YoY; total R&D $92.9M for FY 2025 vs $115.4M in FY 2024.
- Expanded ERAS-0015 license to worldwide rights; composition of matter patents issued for ERAS-0015 and ERAS-4001.

## SEC filing metadata
- accession: 0001193125-26-104105
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/0001193125-26-104105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/eras-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104105
- JSON: https://secwatch.observer/filing/0001193125-26-104105.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104105.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported Q4 2025 results: net income -29.1 million, EPS -0.10.
  - Period: Q4 2025
  - Net income: -29.1 million
  - EPS: -0.10
  - Result: reported results
  source text: Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/0001193125-26-104105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.